https://markets.businessinsider.com/news/stocks/biolinerx-initiates-phase-1-2a-study-of-glix1-1035968176
BioLineRx initiates Phase 1/2a study of GLIX1 | Markets Insider
BioLineRx (BLRX) announced the initiation of a first-in-human, Phase 1/2a study of GLIX1 for the treatment of recurrent and progressive GBM and ...
initiatesphasestudymarketsinsider
https://cordis.europa.eu/project/id/190184696/it
Clinical validation of GLIX1: a small molecule that targets epigenetic changes in cancer cells to...
Glioblastoma Multiform (GBM) patients usually die 12-18 months after diagnosis, with a 5-year survival rate of 6.8%. There are only 5 therapies approved to...